Get a Hartford Courant subscription for less than 29 cents per day
Topics

Vertex Pharmaceuticals Incorporated

Vertex rheumatoid arthritis drug meets study goals

Vertex rheumatoid arthritis drug meets study goals

NEW YORK (Reuters) - Vertex Pharmaceuticals Inc said its experimental oral drug for rheumatoid arthritis met the main goals of a mid-stage study.

Vertex's VX-509 significantly reduced signs and symptoms of the painful condition and disease activity at the two highest of four tested doses compared with a placebo after 12 weeks of treatment, according to results of the 204-patient mid-stage trial released on Tuesday.

The company, which in May launched its first commercial product -- the hepatitis C treatment Incivek -- plans to evaluate VX-509 in a six-month mid-stage study based on results of the 12-week trial.

VX-509 targets a protein known as JAK3, which...

Loading
-6°